• 1
    Boyer TD, Haskal Z. AASLD Practice Guidelines: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. HEPATOLOGY 2005; 41: 386400.
  • 2
    Bureau C, Garcia Pagan JC, Layrargues GP, Metivier S, Bellot P, Perreault P, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27: 742747.
  • 3
    Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, et al.; for Vienna TIPS study group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. HEPATOLOGY 2003; 38: 10431050.
  • 4
    Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 674679.
  • 5
    Henderson JM, Boyer TD, Kutner M, Galloway JR, Rikkers LF, Jeffers LJ, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systemic shunt for variceal bleeding: A randomized trial. Gastroenterology 2006; 130: 16431651.
  • 6
    Boyer TD, Henderson JM, Heerey AM, Arrigain S, Konig V, Connor J, et al. Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt. J Hepatol 2008; 48: 407414.
  • 7
    Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: Long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808815.